Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection

Nathalie Jacobs,† Nathan W. Bartlett,‡ Richard H. Clark§ and Geoffrey L. Smith

Department of Virology, Faculty of Medicine, Imperial College London, St Mary’s Campus, Norfolk Place, London W2 1PG, UK

The vaccinia virus (VACV) N1 protein is an intracellular virulence factor that has a Bcl-2-like structure and inhibits both apoptosis and signalling from the interleukin 1 receptor, leading to nuclear factor kappa B activation. Here, we investigated the immune response to intranasal infection with a virus lacking the N1L gene (vΔN1L) compared with control viruses expressing N1L. Data presented show that deletion of N1L did not affect the proportion of CD4+ and CD8+ T cells infiltrating the lungs or the cytotoxic T-cell activity of these cells. However, vΔN1L induced an increased local natural killer cell activity between days 4 and 6 post-infection. In addition, in the absence of N1 the host inflammatory infiltrate was characterized by a reduced proportion of lymphocytes bearing the early activation marker CD69. Notably, there was a good correlation between the level of CD69 expression and weight loss. The implications of these findings are discussed.

Vaccinia virus (VACV) is a member of the genus Orthopoxvirus (OPV) of the Poxviridae (Moss, 2007; Smith, 2007). Like other OPVs, VACV has a double-stranded DNA genome of approximately 190 kb and encodes about 200 genes. Genes located in the left and right terminal regions of the genome are variable between OPVs and affect virulence, host range and immunomodulation. Gene N1L is located near the left end of the VACV strain Western Reserve (WR) genome and encodes a 14 kDa intracellular homodimer (Bartlett et al., 2002). Bioinformatic analysis showed that the NIL gene is conserved in many OPVs (Bartlett et al., 2002), despite being located in the terminal (variable) region of the genome. An exception to this conservation is the highly attenuated VACV strain modified virus Ankara (MVA) that encodes a truncated N1 protein (Antoine et al., 1998). Overexpression of N1 in uninfected cells was reported to inhibit nuclear factor kappa B (NF-κB) and interferon response factor 3 (IRF3) activation by binding to the inhibitor of kappa kinase (IKK) complex and TANK-binding kinase 1 (TBK1), respectively (DiPerna et al., 2004). However, the crystal structure of N1 showed that this protein is a member of the Bcl-2 family of anti-apoptotic proteins (Aoyagi et al., 2007; Cooray et al., 2007) and it was demonstrated that N1 inhibited staurosporine-induced apoptosis in transfected and infected cells (Cooray et al., 2007). N1 inhibits interleukin (IL)-1-induced NF-κB activation in transfected cells (DiPerna et al., 2004; Graham et al., 2008) but this effect was not evident in infected cells (Cooray et al., 2007), presumably due to the presence of other VACV NF-κB signalling inhibitors. More recently, an additional study showed that N1 did not co-purify or co-precipitate with the IKK complex, unlike another VACV protein, B14 (Chen et al., 2008).

VACV strains engineered to lack the NIL gene are attenuated in mice (Kotwal et al., 1989; Bartlett et al., 2002; Billings et al., 2004). In an intradermal model of infection (Tscharke & Smith, 1999; Jacobs et al., 2006) the deletion mutant, vΔN1L, induced smaller lesion sizes than wild-type (WT) and revertant (Rev) controls and less infectious virus was recovered from the infected tissue (Bartlett et al., 2002). Similarly, vΔN1L was attenuated in the intracranial (Kotwal et al., 1989) and intranasal model of infection (Bartlett et al., 2002). However, the cellular immune response to infection with VACV lacking NIL has not been reported.

Here, we have investigated the effect of N1 on the host response after intranasal infection of female BALB/c mice (6–8 weeks old) with 10^4 p.f.u. of WT VACV, a deletion
mutant lacking N1L (vΔN1L) and a Rev virus (vN1-Rev) in which the N1L gene was reinserted into the N1L gene locus of vAN1L (Bartlett et al., 2002). After infection, groups of mice (n=6) were monitored daily for signs of illness and weights and, as noted previously (Bartlett et al., 2002), animals infected with vAN1L lost less weight than controls (data not shown). In addition, at different days post-infection (p.i.), the animals were sacrificed and the broncho alveolar lavage (BAL) fluids were prepared, and lungs, brain and spleen were removed. Cells present in the lungs were prepared as described previously (Clark et al., 2006) and analysed after staining with appropriate combinations of fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, allophycocyanine (APC)- or tricolour-labelled anti-CD3 (Caltag), anti-CD8 (BD Pharmingen), anti-CD4 (Caltag), anti-CD45 (pan leukocyte marker; BD Pharmingen) anti-CD25 (IL-2Rα; BD Pharmingen), anti-CD69 (BD Pharmingen) or anti-pan NK (DX5; BD Pharmingen) antibodies. The presence of cell-surface markers was determined on a FACScan flow cytometer with CellQuest software (BD Biosciences) and a lymphocyte gate was used to select at least 20 000 events. There was no difference in the proportion of CD4⁺ or CD8⁺ T cells in the lungs at 3, 6 and 9 days p.i. with vAN1L, compared to WT and Rev controls (data not shown). In addition, we measured the cytolytic activity of these cells by chromium release assays on VACV-infected P815 (VACV WR at 10 p.f.u. per cell for 2 h at 37 °C) as described in Clark et al. (2006) and found no difference between the groups at days 6 and 7 p.i. (data not shown). However, in three independent experiments there was an increased proportion of natural killer (NK) cells (CD3⁻ DX5⁺) in the lung (Fig. 1a), and a similar increase was seen in BAL fluid (Fig. 1b). These differences were seen consistently but with these sample sizes were not statistically significant. However, when the cytolytic activity of these cells was measured using Yac-1 target cells (Hussell & Openshaw, 1998), it was found that NK cells derived from infection with vAN1L had significantly greater activity on day 4 p.i. compared with WT and Rev (P<0.05 comparing vAN1L with WT and Rev, Student's t-test) (Fig. 1c). This increased NK activity was observed only locally (lungs) and not in the spleen (data not shown).

Infection by vAN1L induced an increased NK activity at early time points (day 4 p.i.) and therefore we measured if this affected the virus titres in the lungs at different times p.i. By 3 days p.i., the titres of all three viruses had increased to >10⁶ p.f.u. per lung and were indistinguishable from each other, showing that the N1 protein was not needed for efficient virus replication in vivo. However, consistent with the enhanced cytolytic activity of NK cells, by day 7 p.i. the titre of vAN1L in the lung had started to fall, whereas the titres of control viruses were higher than on day 3. At this time point the difference between vAN1L and both control viruses was significant (P<0.05). This difference between vAN1L and controls was increased further by day 10 and at this time the titres of all viruses were starting to fall (Fig. 2). Data shown are the mean

![Fig. 1](image-url)
values from two independent experiments that gave the same result. This observation shows that although vΔN1L can replicate to high titres in mouse tissue, it is cleared more rapidly by the host immune response, consistent with its attenuated phenotype. The increased NK cell activity following infection with vΔN1L may partly explain the reduced virus titres seen at 7 days p.i. However, given the multiple roles of N1 in inhibiting both apoptosis and activation of NF-κB via the IL-1R–TRAF6 pathway, it is probable that other factors may also be involved.

Next, we measured the activation status of the lymphocytes that infiltrated the lung. To do this the percentage of lymphocytes expressing the early activation marker CD69 was measured by FACS (anti-CD69-PE; BD Biosciences). At days 4 and 6 p.i. with WT and Rev virus, ~20 % of lung lymphocytes expressed CD69 and this percentage decreased as the mice recovered from infection (day 11 p.i.) (Fig. 3a). However, on days 4 and 6 p.i. with vΔN1L there was a significantly smaller proportion of lymphocytes (both NK and T cells) that was CD69+ compared with the proportion following infection with WT and Rev viruses (Fig. 3a). This suggests that N1 somehow contributes to immune activation, and, conversely, in the absence of N1 there was a reduced immune activation. In the intranasal model of infection used here, the degree of weight loss correlates with the severity of pneumonia, which is promoted by excessive inflammation. Consequently, diminishing the inflammatory response can reduce illness. This was exemplified by the observation that expression of a secreted CC chemokine-binding protein from VACV strain WR decreased virus virulence in this model. This virus induced less weight loss, decreased virus titres and a reduced recruitment of inflammatory cells into the lungs (Reading et al., 2003).

When the degree of weight loss was compared with CD69 expression it was found that there was a direct relationship: animals that lost more weight (infected by WT and Rev viruses) had a greater percentage of CD69+ cells, while those infected by vΔN1L showed lower weight loss and had a smaller percentage of CD69+ cells (Fig. 3b, P<0.0001).
Although previous in vitro data suggest that CD69 exerts a pro-inflammatory function, recent in vivo results indicate that CD69 might act as a regulatory molecule, modulating the inflammatory response (Sancho et al., 2005). A link between NK activity and CD69 expression was suggested by the observation that, compared with WT mice, CD69−/− mice showed an enhanced NK-mediated anti-tumour response that led to greater protection and rejection of major histocompatibility complex class I low tumour cells (Esplugues et al., 2003). Moreover, antibody against murine CD69, which downregulated CD69 expression, induced NK cytotoxic activity (Esplugues et al., 2005). A relationship between CD69 and Bcl-2 has also been reported. In asthma, eosinophils in BAL expressed CD69 and antibody against human CD69 induced Bcl-2-dependent apoptosis (Foerster et al., 2002).

An interesting parallel to the results reported here with the VACV N1 protein is the reduction in CD69 activation on B cells, which correlated with a decrease in splenomegaly, following infection with murine herpes virus 68 engineered to lack a viral Bcl-2 protein (vBcl-2) (de Lima et al., 2005). Like N1, vBcl-2 is a Bcl-2 family protein that inhibits apoptosis (Wang et al., 1999; Bellows et al., 2000; Ku et al., 2008). Moreover, it was suggested that B cells expressing higher levels of CD69 played a role in viral latency and this role was not directly linked to viral infection of these cells since only a minority of CD69+ B cells were infected (Krug et al., 2007). Another viral anti-apoptotic Bcl-2 protein, M11L from myxoma virus (Kvansakul et al., 1998) also plays a role in inflammation (Opgenorth et al., 1992). While there are parallels between N1, M11 and vBcl-2 in that all these viral proteins are anti-apoptotic, a notable difference is that N1 also inhibits activation of NF-κB, resulting from IL-1R signalling. In accord with this, infection of macrophages in vitro with VACV lacking gene NIL induced the production of pro-inflammatory cytokines, such as alpha and beta interferon, but also immunosuppressive cytokine such as IL-10 (Zhang et al., 2005), suggesting that N1 regulates the inflammatory response in favour of the virus. Moreover, it was described in a tumour model that inhibition of NF-κB in tumour cells induced an upregulation of CD69 on NK co-cultivated with these cells (Jewett et al., 2006).

In conclusion, we demonstrate that deletion of the NIL gene from VACV strain WR causes reduced weight loss and virus titres in the lungs of mice infected intranasally. In this model, loss of N1 promotes a stronger NK cell response to infection but there are fewer CD69+ cells. Therefore, N1 can modulate both the NK response and lymphocyte activation. It remains to be determined whether these effects are due to the ability of N1 to inhibit apoptosis or signalling pathways, leading to NF-κB activation.

Acknowledgements

This work was supported by grants from the Wellcome Trust, European Commission (EC QLRT-2001-01867) and Medical Research Council. G.L.S. is a Wellcome Trust Principal Research Fellow.

References

Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365–396.

Aoyagi, M., Zhai, D., Jin, C., Aleshin, A. E., Stec, B., Reed, J. C. & Liddington, R. C. (2007). Vaccinia virus N1L protein resembles a B lymphoma-2 (Bcl-2) family protein. Protein Sci 16, 118–124.

Bartlett, N., Symons, J. A., Tscharke, D. C. & Smith, G. L. (2002). The vaccinia virus N1 protein is an intracellular homodimer that promotes virulence. J Gen Virol 83, 1965–1976.

Bellows, D. S., Chau, B. N., Lee, P., Lazebnik, Y., Burns, W. H. & Hardwick, J. M. (2000). Antiapoptotic herpesvirus Bcl-2 homologs escape caspase-mediated conversion to proapoptotic proteins. J Virol 74, 5024–5031.

Billings, B., Smith, S. A., Zhang, Z., Lahiri, D. K. & Kotwal, G. J. (2004). Lack of NIL gene expression results in a significant decrease of vaccinia virus replication in mouse brain. Ann N Y Acad Sci 1030, 297–302.

Chen, R. A., Ryzhakov, G., Cooray, S., Randow, F. & Smith, G. L. (2008). Inhibition of IkB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4, e22.

Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith, G. L. (2006). Deletion of gene A41L enhances vaccinia virus immuno-geneicity and vaccine efficacy. J Gen Virol 87, 29–38.

Cooray, S., Bahar, M. W., Abrescia, N. G., McVey, C. E., Bartlett, N. W., Chen, R. A., Stuart, D. I., Grimes, J. M. & Smith, G. L. (2007). Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 88, 1656–1666.

de Lima, B. D., May, J. S., Marques, S., Simas, P. J. & Stevenson, P. G. (2005). Murine gammaherpesvirus 68 bcl-2 homologue contributes to latency establishment in vivo. J Gen Virol 86, 31–40.

DiPerna, G., Stack, J., Bowie, A. G., Boyd, A., Kotwal, G., Zhang, Z., Arvikar, S., Latz, E., Fitzgerald, K. A. & Marshall, W. L. (2004). Poxvirus protein N1L targets the 1-κB kinase complex, inhibits signaling to NF-κB by the tumor necrosis factor superfamiliy of receptors, and inhibits NF-κB and IRF3 signaling by toll-like receptors. J Biol Chem 279, 36570–36578.

Esplugues, E., Sancho, D., Vega-Ramos, J., Martinez, C., Syrbe, U., Haman, A., Engel, P., Sanchez-Madrid, F. & Lauzurica, P. (2003). Enhanced antitumor immunity in mice deficient in CD69. J Exp Med 197, 1093–1106.

Esplugues, E., Vega-Ramos, J., Cartoixa, D., Vazquez, B. N., Salaet, I., Engel, P. & Lauzurica, P. (2005). Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. Blood 105, 4399–4406.

Foerster, M., Haefner, D. & Kroegei, C. (2002). Bcl-2-mediated regulation of CD69-induced apoptosis of human eosinophils: identification and characterization of a novel receptor-induced mechanism and relationship to CD95-transduced signalling. Scand J Immunol 56, 417–428.

Graham, S. C., Bahar, M. W., Cooray, S., Chen, R. A., Whalen, D. W., Abrescia, N. G. A., Alderton, D., Owens, R. J., Stuart, D. I., Smith, G. L. & Grimes, J. M. (2008). Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-κB rather than apoptosis. PLoS Pathog 4, e1000128.

Hussell, T. & Openshaw, P. J. (1998). Intracellular IFN-γ expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J Gen Virol 79, 2593–2601.

Jacobs, N., Chen, R. A., Gubser, C., Najarro, P. & Smith, G. L. (2006). Intradermal immune response after infection with vaccinia virus. J Gen Virol 87, 1157–1161.

Jewett, A., Cacalano, N. A., Teruel, A., Romero, M., Rashedi, M., Wang, M. & Nakamura, H. (2006). Inhibition of nuclear factor kappa B (NF-κB)
activity in oral tumor cells prevents depletion of NK cells and increases their functional activation. Cancer Immunol Immunother 55, 1052–1063.

Kotwal, G. J., Hugin, A. W. & Moss, B. (1989). Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology 171, 579–587.

Krug, L. T., Moser, J. M., Dickerson, S. M. & Speck, S. H. (2007). Inhibition of NF-κB activation in vivo impairs establishment of gammaherpesvirus latency. PLoS Pathog 3, e11.

Ku, B., Woo, J. S., Liang, C., Lee, K. H., Hong, H. S., E., X., Kim, K. S., Jung, J. U. & Oh, B. H. (2008). Structural and biochemical bases for the inhibition of autophagy and apoptosis by viral Bcl-2 of murine gamma-herpesvirus 68. PLoS Pathog 4, e25.

Kvansakul, M., van Delft, M. F., Lee, E. F., Gulbis, J. M., Fairlie, W. D., Huang, D. C. & Colman, P. M. (2007). A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak. Mol Cell 25, 933–942.

Moss, B. (2007). Poxviridae: the viruses and their replication. In Fields Virology, 5th edn, pp. 2905–2946. Edited by D. M. Knipe. Philadelphia: Lippincott Williams & Wilkins.

Opgenorth, A., Graham, K., Nation, N., Strayer, D. & McFadden, G. (1992). Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J Virol 66, 4720–4731.

Reading, P. C., Symons, J. A. & Smith, G. L. (2003). A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. J Immunol 170, 1435–1442.

Sancho, D., Gomez, M. & Sanchez-Madrid, F. (2005). CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 26, 136–140.

Smith, G. L. (2007). Genus Orthopoxvirus: Vaccinia virus. In Poxviruses, pp. 1–45. Edited by A. A. Mercer, A. Schmidt & O. Weber. Berlin: Birkhauser-Verlag.

Tscharke, D. C. & Smith, G. L. (1999). A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 80, 2751–2755.

Wang, G. H., Garvey, T. L. & Cohen, J. I. (1999). The murine gammaherpesvirus-68 M11 protein inhibits Fas- and TNF-induced apoptosis. J Gen Virol 80, 2737–2740.

Zhang, Z., Abrahams, M. R., Hunt, L. A., Suttle, J, Marshall, W., Lahiri, D. K. & Kotwal, G. J. (2005). The vaccinia virus N1L protein influences cytokine secretion in vitro after infection. Ann N Y Acad Sci 1056, 69–86.